The new fund will invest growth equity in innovative companies across medical products, diagnostics, life sciences tools, digital health, and pharmaceutical outsourcing services, primarily in the UK.
NIHR Industry Hub are partnering with Apposite Capital to maximise the fund’s impact by helping to identify and support healthcare companies that are ready to scale-up. For companies that will be progressing through the NIHR Innovation Catalyst this creates a natural bridge, providing a seamless ‘off-ramp’ to secure scale-up capital.
But there’s more to scaling-up than funding. HealthTech innovation often stalls because evidence pathways are unclear and evaluation is slow.
To help bridge the scale-up gap NIHR support all HealthTech innovators by providing a clear, single pathway to evaluate your technology and generate the evidence needed for adoption within the NHS.
Read the full British Bank announcement here
They will provide:
- Access to HealthTech Research Centres and clinical expertise
- Structured evaluation pathways in NHS settings
- Real-world testing in active NHS environments
- Real-world evidence generation for market adoption
- Support to define and deliver your evidence strategy
This support is not just available to Apposite Capital grant recipients.
Contact enquiries@nihr.ac.uk if you want to generate evidence faster and reduce time to adoption.
Read the full blueprint for UK commercial research delivery here; to learn about more about NIHR's coordinated SME entry and progression model for MedTech, diagnostics, digital health and AI companies.